LEADER 01406nam  2200361   450 
001 9910674034803321
005 20230626210537.0
035   $a(CKB)5400000000044483
035   $a(NjHacI)995400000000044483
035   $a(EXLCZ)995400000000044483
100   $a20230626d2022      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aImmunotherapy in Myeloma $eA Theme Issue in Honor of Prof. Dr. Go?sta Gahrton /$fNicolaus Kro?ger, Laurent Garderet
210  1$aBasel :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2022.
215   $a1 online resource (124 pages)
311   $a3-0365-2906-3 
330   $aImmunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy.
517   $aImmunotherapy in Myeloma 
606   $aMedicine
615  0$aMedicine.
676   $a610
700   $aKro?ger$b Nicolaus$01214304
702   $aGarderet$b Laurent
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910674034803321
996   $aImmunotherapy in Myeloma$93390841
997   $aUNINA